Wall Street brokerages forecast that Vericel (NASDAQ:VCEL) will announce earnings of ($0.15) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Vericel’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.16). Vericel reported earnings per share of ($0.31) during the same quarter last year, which suggests a positive year-over-year growth rate of 51.6%. The company is expected to report its next earnings results on Wednesday, May 9th.
On average, analysts expect that Vericel will report full-year earnings of ($0.34) per share for the current year, with EPS estimates ranging from ($0.37) to ($0.30). For the next year, analysts expect that the firm will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.30) to ($0.05). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Vericel.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. The company had revenue of $23.35 million for the quarter.
VCEL has been the topic of several recent research reports. ValuEngine upgraded Vericel from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub cut Vericel from a “strong-buy” rating to a “buy” rating in a report on Friday, March 30th. BTIG Research set a $8.00 price objective on Vericel and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Needham & Company LLC lifted their price objective on Vericel from $5.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 6th. Finally, Ladenburg Thalmann cut Vericel from a “buy” rating to a “neutral” rating in a report on Tuesday, March 6th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Vericel has an average rating of “Buy” and a consensus price target of $14.25.
NASDAQ VCEL traded down $0.20 during trading hours on Tuesday, hitting $11.80. 611,520 shares of the company were exchanged, compared to its average volume of 940,579. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57. Vericel has a 52-week low of $2.35 and a 52-week high of $13.20. The company has a market cap of $429.98, a price-to-earnings ratio of -23.60 and a beta of 3.18.
A number of institutional investors have recently added to or reduced their stakes in VCEL. JPMorgan Chase & Co. purchased a new position in Vericel during the third quarter worth $328,000. Bank of Montreal Can purchased a new position in Vericel during the fourth quarter worth $140,000. Perkins Capital Management Inc. increased its position in Vericel by 2.9% during the fourth quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock worth $3,155,000 after buying an additional 16,350 shares in the last quarter. First Washington CORP increased its position in Vericel by 20.1% during the fourth quarter. First Washington CORP now owns 809,027 shares of the biotechnology company’s stock worth $4,409,000 after buying an additional 135,600 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Vericel by 1,374.2% during the fourth quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after buying an additional 27,992 shares in the last quarter. 36.91% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect Vericel (VCEL) to Announce -$0.15 EPS” was published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://macondaily.com/2018/04/22/brokerages-expect-vericel-vcel-to-announce-0-15-eps.html.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Get a free copy of the Zacks research report on Vericel (VCEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.